Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Axogen, Inc. filings on SEC EDGAR ↗
Axogen, Inc. filed a corporate presentation and hosted an investor event on November 9, 2026, to announce its decision to move forward with a commercial market launch for prostate nerve reconstruction. The presentation highlights the clinical need and market opportunity for using Avance Nerve Allograft to restore erectile function and quality of life following robotic-assisted radical prostatectomies.
Axogen reported Q3 2026 revenue of $75.8 million, a 26.2% increase year-over-year, and raised its full-year revenue guidance to at least $290 million. The company also highlighted the completion of its BioCircuit Technologies acquisition and a successful $225 million equity raise during the period.
“We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s strategic plan priorities. Our strong growth across all markets, continues to validate our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our 2026 revenue guidance and longer-term strategic objectives.”
Axogen M&A Deal with BioCircuit Technologies, Inc.
Axogen, Inc. has completed its acquisition of BioCircuit Technologies, Inc., a developer of NerveTape™, the first FDA-cleared sutureless device for peripheral nerve repair. The acquisition is expected to contribute approximately $34 million to Axogen's 2027 revenue and aligns with the company's mission to restore peripheral nerve function.